Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Gerald Sandler

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
Transfusion|December 3, 2014
It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work GroupS Gerald Sandler, Willy A Flegel, Connie M Westhoff, et al.
Transfusion|March 13, 2020
It's time to phase out "serologic weak D phenotype" and resolve D types with RHD genotyping including weak D type 4Willy A Flegel, Gregory A Denomme, John T Queenan, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
Transfusion|December 3, 2014
It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work GroupS Gerald Sandler, Willy A Flegel, Connie M Westhoff, et al.
Transfusion|March 13, 2020
It's time to phase out "serologic weak D phenotype" and resolve D types with RHD genotyping including weak D type 4Willy A Flegel, Gregory A Denomme, John T Queenan, et al.
Pageof 6